Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

Evommune

Status and phase: Enrolling; Phase 2

Conditions: Eczema Atopic Dermatitis; Atopic Dermatitis (AD); Eczema

Treatments: Biological: Placebo; Biological: EVO301

Study type: Interventional

Funder types: Industry

Identifiers

NCT06723405

EVO301-AD001

Details and patient eligibility

About

This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.

Full description

This is a Phase 2a efficacy and safety study of intravenous EVO301 in adults with moderate to severe atopic dermatitis.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Males or non-pregnant, non-lactating females, age 18 years or older
2. Chronic atopic dermatitis for at least 6 months
3. BSA of AD involvement of at least 10%
4. EASI score of at least 16.

Exclusion criteria

1. Significant AD flare with 4 weeks
2. Use of biologic therapy within 12 weeks
3. Regular use of tanning booth within 4 weeks
4. Skin condition that could interfere with study assessments

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 2 patient groups, including a placebo group

Intravenous EVO301

Experimental group

Treatment:

Biological: EVO301

Placebo

Placebo Comparator group

Treatment:

Biological: Placebo